An observational study in Polio, Measles and Rubella, sponsored by China National Biotec Group Company Limited. Not yet recruiting at 6 sites in China. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Observational
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
This is a follow-up study of several previous clinical trials (A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) : NCT04054882, NCT04638985; A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA): NCT04053010, NCT04636827). Five years after vaccination with sIPV, MMR or HepA-L, blood samples were collected from the followed-up children to assess the antibody levels and seropositive rates against polio, measles, rubella, mumps and hepatitis A. This study was conducted in six provinces of China.
274 studies on the registry are indexed under Poliomyelitis; 18 are open to participants now.
This study's planned enrollment of 600 is close to the median of 600 across 21 observational studies indexed under Poliomyelitis.
Browse Poliomyelitis studies →China National Biotec Group Company Limited is the lead sponsor of 37 studies on the registry; 2 are open to participants now.
First submitted after China National Biotec Group Company Limited became part of Sinopharm.
Counted across the registry records on this site, refreshed daily.
Participants who have taken part in the NCT04638985 or NCT04636827 trials and have completed the designated batches of sIPV, MMR or HepA-L vaccinations, with a time interval of 60 to 66 months since the fourth dose of sIPV, the second dose of MMR or the first dose of HepA-L vaccination at the time of enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All the children who met the protocol criteria and had been five years since their last doses of sIPV, MMR or HepA-L were included.
seropositive rates of antibodies against poliovirus
The percentage of participants with positive antibody(titre ≥ 8) against all three serotypes of poliovirus 5 years after the four doses of sIPV immunization.
Time frame: 5 years after the four doses of sIPV immunization
seropositive rates of antibodies against measles, rubella, mumps
The percentage of participants with positive antibody against measles, rubella, mumps 5 years after the two doses of MMR immunization.
Time frame: 5 years after the two doses of MMR immunization
seropositive rates of antibodies against hepatitis A
The percentage of participants with positive antibody against hepatitis A 5 years after the one doses of HepA-L immunization.
Time frame: 5 years after the one doses of HepA-L immunization
GMTs of antibodies against poliovirus
The GMTs of participants against all three serotypes of poliovirus 5 years after the four doses of sIPV immunization.
Time frame: 5 years after the four doses of sIPV immunization
GMCs of antibodies against measles, rubella, mumps
The GMCs of participants against measles, rubella, mumps 5 years after the two doses of MMR immunization.
Time frame: 5 years after the two doses of MMR immunization
GMCs of antibodies against hepatitis A
The GMCs of participants against hepatitis A 5 years after the one doses of HepA-L immunization.
Time frame: 5 years after the one doses of HepA-L immunization
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Biotec Group Company Limited →